1.Date of the resolution of the board of directors or
shareholders meeting:2026/11/12
2.Content of the investment plan:
expansion plan for high-activity injectable filling line
3.Projected monetary amount of the investment:NT$900 million
4.Projected date of the investment:2026~2029
5.Source of capital funds:Operating capital
6.Specific purpose:In order to capture a share of the huge global market for
highly active anticancer drugs and next-generation ADC biosimilars, we are
expanding our injectable product filling line.
7.Any other matters that need to be specified:None